Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H38N2O4.ClH |
Molecular Weight | 491.063 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=C(OC)C=C(CCN(C)CCC[C@@](C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
InChI
InChIKey=DOQPXTMNIUCOSY-HZPIKELBSA-N
InChI=1S/C27H38N2O4.ClH/c1-20(2)27(19-28,22-10-12-24(31-5)26(18-22)33-7)14-8-15-29(3)16-13-21-9-11-23(30-4)25(17-21)32-6;/h9-12,17-18,20H,8,13-16H2,1-7H3;1H/t27-;/m1./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17646169 | http://www.google.ch/patents/US5889060http://adisinsight.springer.com/drugs/800007413Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17646169 |
http://adisinsight.springer.com/drugs/800022706 | http://www.drugdevelopment-technology.com/projects/rezular/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646169 | http://www.google.ch/patents/US5889060http://adisinsight.springer.com/drugs/800007413
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/17646169 |
http://adisinsight.springer.com/drugs/800022706 | http://www.drugdevelopment-technology.com/projects/rezular/
Dexverapamil (R-verapamil) is an enantiomer of verapamil. R-isomer behaved as an inhibitor of multidrug-resistant protein MRP1 (involved in the cancer cell multidrug resistance phenotype). It was developed by Knoll (BASF Pharma) as a chemosensitiser and/or modulator of multidrug resistance for use in combination with cancer chemotherapy. Dexverapamil was undergoing phase II clinical studies in France, Italy, Spain, United Kingdom and the US in patients with various cancers. It was also undergoing phase I clinical trials in Japan where it was licensed to Mitsui and Mitsui Toatsu Chemicals. However, development was discontinued. Dexverapamil (R-verapamil) has been developing by AGI therapeutics for the treatment of Irritable bowel syndrome however development was discontinued.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1767178 | http://adisinsight.springer.com/drugs/800007413
Curator's Comment: Verapamil was fisrt synthetized by German pharmaceutical firm Knoll (D365). Verapamil is a recamic mixture of R and S enantiomers. R-verapamil has been developing by AGI therapeutics for the treatment of Irritable bowel syndrome. http://adisinsight.springer.com/drugs/800022706
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P08183 Gene ID: 5243.0 Gene Symbol: ABCB1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646169 |
|||
Target ID: CHEMBL3004 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646169 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | REZULAR Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Sources: http://www.google.ch/patents/US5889060 |
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2103 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
308 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
892 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11818 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1707 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3974 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
5.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
250 mg single, oral dose: 250 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8398588/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
DEXVERAPAMIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. | 2002 Jan |
|
Chrono: a community-based hypertension trial of a chronotherapeutic formulation of verapamil. | 2002 Nov-Dec |
|
Population analyses of sustained-release verapamil in patients: effects of sex, race, and smoking. | 2003 Jan |
|
Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. | 2003 May |
|
Novel chewable sustained-release tablet containing verapamil hydrochloride. | 2004 |
|
St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. | 2004 Apr |
|
Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. | 2004 Feb |
|
Pharmacodynamics of controlled release verapamil in patients with hypertension: an analysis using spline functions. | 2004 Jul |
|
Effect of supranutritional and organically bound selenium on performance, carcass characteristics, and selenium distribution in finishing beef steers. | 2004 May |
|
Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase. | 2005 Apr 25 |
|
Phosphorus-doped and undoped glassy carbon indicator electrodes in controlled-current potentiometric titrations of bromide- or chloride-containing active ingredients in some pharmaceutical preparations. | 2005 Feb 23 |
|
Efficacy of using a combination of rendered protein products as an undegradable intake protein supplement for lactating, winter-calving, beef cows fed bromegrass hay. | 2005 Jan |
|
The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. | 2006 Mar |
|
The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. | 2006 Oct |
|
Corn oil supplementation to steers grazing endophyte-free tall fescue. I. Effects on in vivo digestibility, performance, and carcass traits. | 2007 May |
|
Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. | 2007 Nov |
|
(R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. | 2007 Oct 26 |
|
Manure nutrient excretion by lactating cows fed exogenous phytase and cellulase. | 2007 Sep |
|
Studies of verapamil binding to human serum albumin by high-performance affinity chromatography. | 2008 Dec 1 |
|
Effects of divergent selection for serum insulin-like growth factor-I concentration on performance, feed efficiency, and ultrasound measures of carcass composition traits in Angus bulls and heifers. | 2008 Nov |
|
Role of multidrug transporters in neurotherapeutics. | 2009 Apr |
|
Effect of calcium-regulating hormones and calcium channel modulators on glucose consumption by muscle and adipose tissues in vivo and in vitro. | 2009 Aug |
|
Determinants of quality of life of youths in an English-speaking Caribbean nation. | 2009 Dec |
|
Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. | 2009 Nov |
|
(E)-4-Bromo-N-(2,3-dimeth-oxy-benzyl-idene)aniline. | 2010 Aug 4 |
|
Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism. | 2010 Dec 14 |
|
The synthesis and characterization of cellular membrane affinity chromatography columns for the study of human multidrug resistant proteins MRP1, MRP2 and human breast cancer resistant protein BCRP using membranes obtained from Spodoptera frugiperda (Sf9) insect cells. | 2010 Jun 15 |
|
Effect of feeding alfalfa hay or Tifton 85 bermudagrass haylage with or without a cellulase enzyme on performance of Holstein cows. | 2010 Nov |
|
Assessment of pulmonary function and serum substance levels in newborn and juvenile rats. | 2010 Nov |
|
Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. | 2010 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.google.ch/patents/US5889060
Administration of (R)-verapamil may be by any of the conventional routes, for instance oral, intravenous, sublingual, topical and rectal. Conventional formulations may verapamil will be formulated for oral administration. Typically, a suitable dosage of the active component is up to 500 mg per day, but any of the standard dosages for the racemate may be used.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646169
Curator's Comment: in vitro dexverapamil can enhance doxorubicin cytotoxicity in P388/Dx cells with a much greater effect depending on the treatment scheme used, by increasing the intracellular content of drug.
https://www.ncbi.nlm.nih.gov/pubmed/9199659/
It was investigated the individual effects of each enantiomer by comparison with the racemic mixture. The cellular effects were tested on both control and human MRP1 cDNA-transfected baby hamster kidney 21 (BHK-21) cells (MRP1-BHK-21). Racemic verapamil was cytotoxic for MRP1-BHK-21 cells at concentrations <10-20 μM, which were ineffective in control BHK-21 cells. The R- and S-enantiomers were highly discriminated because (R)-verapamil did not exhibit any cytotoxicity for the two types of cell, whereas (S)-verapamil displayed a killing activity, even more potent than that observed with the racemic mixture at the same concentration.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
B0P742MK5O
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
38176-02-2
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
C156452
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
253-810-3
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
170014
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
632821
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | |||
|
m11414
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID80959103
Created by
admin on Sat Dec 16 04:55:27 GMT 2023 , Edited by admin on Sat Dec 16 04:55:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD